The COVID-19 outbreak is requiring the pharma and biotech industry to reallocate current and long-term priorities both in business practices and in everyday life. We are actively consulting clients on adaptive strategies to mitigate risks associated with conducting clinical trials. Our Services team continues to take actions necessary to help clients and their clinical trial staff focus on patient safety.
We encourage clients to consult recent guidance from FDA and the appropriate national and regional medicines authorities. Accordingly, Suvoda commits to support our clients with shifting trial protocol needs, clinical supply chain disruptions, and to help document contingency measures as needed. We’ve created a COVID-19 Response Team (CRT) to monitor regional impacts, align with government orders and communicate changes accordingly.
As we actively monitor developments, we have a number of internal initiatives in place to prioritize the safety and health of our employees, as well as minimize the risk of disruptions to our clients’ clinical trials. We have:
More than ever, we remain true to our mission and values as a company. In ordinary times, our team at Suvoda has committed to implementing creative solutions for complex problems. In times like these, we remain just as diligent. As always, we are laser-focused on providing seamless, exceptional service to our clients so they can continue to provide treatments to their patients faster and more efficiently.
We continue to serve our clients by making global clinical trial operations easier to run. We’ve always emphasized the need to adapt, and we resolve to help companies in the biopharma space continue to evolve in the face of seismic shifts in the industry. We’re in this together.
If you have specific questions about how to use our IRT to navigate risks and document modifications to protocol and trial delivery, please reach out to your assigned Suvoda project manager or sales representative.
President & CEO